Jason Sicklick

30PUBLICATIONS
75CO-AUTHORS
Molecular targetsPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Solid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Jul 13, 2026
Radiographic Versus Pathology-Integrated Response for Assessing Optimal Surgical Timing After Neoadjuvant Imatinib in Patients With Locally Advanced KIT Exon 11-Mutant GIST.

|May 25, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

|May 05, 2026
GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy.

|Apr 20, 2026
Cytoreductive Surgery in Patients With Metastatic Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors.

|Jan 08, 2026
Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.

Jason K Sicklick, Daisuke Nishizaki, Hirotaka Miyashita

|Sep 12, 2025
B7-H3/CD276: Novel Immune Checkpoint and Jack of All Trades.

Brigid Larkin, Daisuke Nishizaki, Hirotaka Miyashita

Pageof 5

Frequent Collaborators

14 joint publications

Razelle Kurzrock

9 joint publications

Ryosuke Okamura

9 joint publications

Shumei Kato

6 joint publications

Suzanna Lee